Kelly Hoover, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 977 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 977 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$986
- plus $6K from 27 others
What the payments were for
- Food & beverage$15,44498%
- Education$3892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 155 | $2,215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 139 | $2,196 |
| Alkermes, Inc. | 107 | $1,734 |
| Otsuka America Pharmaceutical, Inc. | 89 | $1,306 |
| Vanda Pharmaceuticals Inc. | 63 | $1,270 |
| Teva Pharmaceuticals USA, Inc. | 45 | $986 |
| Johnson & Johnson | 62 | $983 |
| Sunovion Pharmaceuticals Inc. | 64 | $789 |
| Harmony Biosciences LLC | 44 | $614 |
| Supernus Pharmaceuticals, Inc. | 26 | $588 |
| Lundbeck LLC | 35 | $573 |
| Neurocrine Biosciences, Inc. | 40 | $555 |
| E.r. Squibb & Sons, L.L.C. | 19 | $402 |
| Axsome Therapeutics, Inc. | 11 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $211 |
| Indivior Inc. | 8 | $165 |
| Almatica Pharma LLC | 8 | $150 |
| Merck | 7 | $91 |
| Idorsia Pharmaceuticals US Inc | 6 | $90 |
| Bausch Health US, LLC | 4 | $81 |
| Eisai Inc. | 5 | $80 |
| Noven Therapeutics, LLC | 4 | $77 |
| Avanir Pharmaceuticals, Inc. | 5 | $72 |
| Jazz Pharmaceuticals Inc. | 5 | $72 |
| Corium, LLC | 3 | $55 |
| Collegium Pharmaceutical, Inc. | 3 | $52 |
| Neuronetics, Inc. | 1 | $41 |
| Biogen | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Neos Therapeutics, LP | 1 | $19 |
| Gilead | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,833 in reported general payments places this provider in the 95th percentile of 216 medical providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 119 | $154,847 |
| CaplytaLumateperone Tosylate | 70 | $135,512 |
| Invega SustennaPaliperidone Palmitate | 37 | $109,120 |
| VraylarCariprazine Hcl | 59 | $85,142 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $54,631 |
| AristadaAripiprazole Lauroxil | 13 | $48,914 |
| UzedyRisperidone | 21 | $34,658 |
| RexultiBrexpiprazole | 16 | $25,463 |
| BelsomraSuvorexant | 15 | $7,121 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,903 |
| Aripiprazole | 115 | $5,980 |
| Vilazodone Hcl | 45 | $5,394 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,356 |
| DayvigoLemborexant | 13 | $4,314 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $2,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $983 | $263,968156 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,196 | $135,51270 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,734 | $103,54544 claims |
| AbbVieVraylar | $2,215 | $85,14259 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $986 | $34,65821 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,306 | $25,46316 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $211 | $11,25924 claims |
| MerckBelsomra | $91 | $7,12115 claims |
| Eisai Inc.Dayvigo | $80 | $4,31413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 medical providers in Nebraska.
Other medical in Omaha
- Jacob RidderOmaha$12K
- Angelika StevensOmaha$8K
- Jennelea MontanezOmaha$8K
- Kristina DadaOmaha$7K
- Saundra BrennanOmaha$6K
- Collin HortonOmaha$6K
- Karla LessmanOmaha$5K
- Lynn McLaughlinOmaha$4K
- Hannah PickOmaha$4K
- Rebecca BertucciOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.